HomeCompareADXS vs VICI

ADXS vs VICI: Dividend Comparison 2026

ADXS yields 331.37% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADXS wins by $2986.34M in total portfolio value
10 years
ADXS
ADXS
● Live price
331.37%
Share price
$0.60
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2987.30M
Annual income
$1,874,518,858.21
Full ADXS calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — ADXS vs VICI

📍 ADXS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodADXSVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ADXS + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ADXS pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ADXS
Annual income on $10K today (after 15% tax)
$28,166.68/yr
After 10yr DRIP, annual income (after tax)
$1,593,341,029.48/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, ADXS beats the other by $1,592,824,759.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ADXS + VICI for your $10,000?

ADXS: 50%VICI: 50%
100% VICI50/50100% ADXS
Portfolio after 10yr
$1494.13M
Annual income
$937,563,117.17/yr
Blended yield
62.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

ADXS
Analyst Ratings
6
Buy
2
Hold
Consensus: Buy
Altman Z
-24.8
Piotroski
1/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ADXS buys
0
VICI buys
0
No recent congressional trades found for ADXS or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricADXSVICI
Forward yield331.37%6.52%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$2987.30M$966.2K
Annual income after 10y$1,874,518,858.21$607,376.13
Total dividends collected$2879.16M$926.2K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ADXS vs VICI ($10,000, DRIP)

YearADXS PortfolioADXS Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$43,837$33,137.27$11,361$941.49+$32.5KADXS
2$182,667$135,761.45$13,320$1,481.32+$169.3KADXS
3$724,155$528,700.93$16,284$2,405.01+$707.9KADXS
4$2,733,677$1,958,830.81$21,040$4,071.78+$2.71MADXS
5$9,835,841$6,910,807.10$29,209$7,285.49+$9.81MADXS
6$33,762,918$23,238,567.70$44,443$14,006.51+$33.72MADXS
7$110,677,420$74,551,098.17$75,822$29,512.55+$110.60MADXS
8$346,821,277$228,396,437.05$148,733$69,726.75+$346.67MADXS
9$1,039,984,991$668,886,225.19$344,394$189,413.75+$1039.64MADXS
10$2,987,302,799$1,874,518,858.21$966,234$607,376.13+$2986.34MADXS

ADXS vs VICI: Complete Analysis 2026

ADXSStock

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

Full ADXS Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this ADXS vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ADXS vs SCHDADXS vs JEPIADXS vs OADXS vs KOADXS vs MAINADXS vs NNNADXS vs EPRTADXS vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.